5.7 Use in Pregnancy There are no adequate and well-controlled studies of ADCETRIS in pregnant women. However, based on its mechanism of action and findings in animals, ADCETRIS can cause fetal harm when administered to a pregnant woman. Brentuximab vedotin caused embryo-fetal toxicities, including...
brentuximab vedotinCD30GVHDHodgkin's lymphomaperipheral neuropathystem cell transplantationMechanism of action: Anti-CD30 antibody conjugated to monomethyl auristatin E (MMAE): MMAE is a synthetic tubulin disrupting agent. It is an analog of the marine natural product dolastatin 10. It binds to ...
Embryo-fetal toxicity:Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patie...
Brentuximab vedotin是一种ADC。该抗体是针对CD30的嵌合IgG1。小分子MMAE是一种微管破坏剂。 MMAE通过接头共价连接到抗体上。 非临床数据表明ADCETRIS的抗癌活性归因于ADC与表达CD30的细胞的结合,随后是ADC-CD30复合物的内化以及通过蛋白水解切割释放MMAE。MMAE与微管蛋白的结合破坏细胞内的微管网络,随后诱导细胞周期停滞...
Embryo-fetal toxicity:Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus, and to avoid pregnancy during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS. ...
Embryo-fetal toxicity:Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus, and to avoid pregnancy during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS. ...
Embryo-fetal toxicity: Based on the mechanism of action and findings in animals, ADCETRIS can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should avoid pregnancy during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS. ...
Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target anti
Brentuximab vedotin, a CD30-directed antibody-drug conjugate (ADC), is approved for treating certain patients with CD30-expressing hematologic malignancies. Its primary mechanism of action is the targeted delivery of a microtubule-disrupting agent, monomethyl auristatin E (MMAE), to CD30-expressing ...